# A Study of SHR6508 in Secondary Hyperparathyroidism

> **NCT05663411** · PHASE2 · UNKNOWN · sponsor: **Shanghai Hengrui Pharmaceutical Co., Ltd.** · enrollment: 75 (actual)

## Conditions studied

- Secondary Hyperparathyroidism

## Interventions

- **DRUG:** SHR6508
- **DRUG:** SHR6508
- **DRUG:** Cinacalcet

## Key facts

- **NCT ID:** NCT05663411
- **Lead sponsor:** Shanghai Hengrui Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-02-24
- **Primary completion:** 2023-10-31
- **Final completion:** 2023-11-30
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2023-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05663411

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05663411, "A Study of SHR6508 in Secondary Hyperparathyroidism". Retrieved via AI Analytics 2026-09-24 from https://api.ai-analytics.org/clinical/NCT05663411. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*